Barry Greene Buys Shares of Dyne Therapeutics, Inc. $DYN
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barry Greene, insider at Dyne Therapeutics, Inc. ($DYN), bought 57,463 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Dyne Therapeutics, Inc. Stock Down 19.2%
Shares of Dyne Therapeutics, Inc. ($DYN) traded around $20.26 on Wednesday, down 19.2% for the day.
Dyne Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Get Dyne Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.